Drug Profile
Research programme: cancer therapies - Advinus Therapeutics/H. Lee Moffitt Cancer Center and Research Institute
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Advinus Therapeutics; H. Lee Moffitt Cancer Center and Research Institute
- Developer H. Lee Moffitt Cancer Center and Research Institute
- Class
- Mechanism of Action Raf kinase inhibitors; Retinoblastoma protein inhibitors; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in USA
- 18 Jun 2013 Early research in Cancer in USA (unspecified route)